Table 2 Incidences of residual respiratory symptoms (primary outcome) and long COVID-19 (secondary outcome)
From: Effects of antivirals on patients with COVID-19 breakthrough
n | Primary outcome | Secondary outcome | |||||
|---|---|---|---|---|---|---|---|
Event n (%) | Person-days1 | Event n (%) | Unadjusted rate2 (95% CI) | Adjusted rate2,3 (95% CI) | |||
SoC | 68 | 19 (27.9) | 2777 | 8 (11.8) | 28.8 (12.4–56.8) | 30.0 (14.6–61.6) | |
SoC + antiviral | 74 | 15 (20.3) | 2756 | 6 (8.1) | 21.8 (8.0–47.4) | 21.0 (9.1–48.3) | |
Favipiravir | 5 | 0 (0.0) | 69 | 1 | 144.9 (3.7–807.5) | 300.0 (142.4–631.8) | |
Molnupiravir | 68 | 14 (20.6) | 2603 | 5 | 19.2 (6.2–44.8) | 18.6 (1.7–198.2) | |
Remdesivir | 1 | 1 (100.0) | 84 | 0 | – | – | |